Scaffold-based osteogenic dual delivery system with melatonin and BMP-2 releasing PLGA microparticles

2021 ◽  
Vol 600 ◽  
pp. 120489
Author(s):  
Hala Jarrar ◽  
Damla Çetin Altındal ◽  
Menemşe Gümüşderelioğlu
2019 ◽  
Vol 64 (No. 7) ◽  
pp. 287-293
Author(s):  
J Matejkova ◽  
P Podhorec

Many fish species display some form of reproductive disorder in captivity. Captive fish reared in conditions outside the natural spawning environment show a failure of the pituitary to release the maturational gonadotropin luteinizing hormone thus necessitating administration of the hormone to induce spawning. A controlled sustained-release delivery system can conquer the issue of short half-life of gonadotropin releasing hormone (GnRH) in blood and avoid the necessity of using re-injections. Sustained release of GnRHa can induce long-term enhancement in semen production and multiple spawning in species with asynchronous or multiple batch group synchronous ovarian physiology. The most recent development is the incorporation of GnRHa into microparticles of biodegradable polymers that release the drug during a certain period of time ranging from days to weeks. The most attractive polymeric candidate used as a carrier for administering a pharmaceutical products is poly(lactic-co-glycolic acid); (PLGA). PLGA has excellent biodegradability and biocompatibility and is generally recognised as safe by international regulatory agencies including the European Medicines Agency and the United States Food and Drug Administration. This review describes methods of hormonal treatment in fish, highlights the advantage of sustained drug delivery system and discusses the potential of PLGA microparticles as a tool for achieving successful reproduction.


2010 ◽  
Vol 24 (S1) ◽  
Author(s):  
Anderson J Gomes ◽  
Naiara A Oliveira ◽  
Talita JS Alves ◽  
Marta ST Rocha ◽  
Ricardo B Azevedo

2006 ◽  
Vol 175 (4S) ◽  
pp. 323-324 ◽  
Author(s):  
Joseph Dall'era ◽  
Sweaty Koul ◽  
Jesse Mills ◽  
Jeremy Myers ◽  
Randall B. Meacham ◽  
...  

VASA ◽  
2017 ◽  
Vol 46 (6) ◽  
pp. 452-461 ◽  
Author(s):  
Klaus Amendt ◽  
Ulrich Beschorner ◽  
Matthias Waliszewski ◽  
Martin Sigl ◽  
Ralf Langhoff ◽  
...  

Abstract. Background: The purpose of this observational study is to report the six-month clinical outcomes with a new multiple stent delivery system in patients with femoro-popliteal lesions. Patients and methods: The LOCOMOTIVE study is an observational multicentre study with a primary endpoint target lesion revascularization (TLR) rate at six months. Femoro-popliteal lesions were prepared with uncoated and/or paclitaxel-coated peripheral balloon catheters. When flow limiting dissections, elastic recoil or recoil due to calcification required stenting, up to six short stents per delivery device, each 13 mm in length, were implanted. Sonographic follow-ups and clinical assessments were scheduled at six months. Results: For this first analysis, a total of 75 patients 72.9 ± 9.2 years of age were enrolled. The majority of the 176 individually treated lesions were in the superficial femoral artery (76.2 %, 134/176) whereas the rate of TASC C/D amounted to 51.1 % (90/176). The total lesion length was 14.5 ± 9.0 cm with reference vessel diameters of 5.6 ± 0.7 mm. Overall 47 ± 18 % of lesion lengths could be saved from stenting. At six months, the patency was 90.7 % (68/75) and all-cause TLR rates were 5.3 % (4/75) in the overall cohort. Conclusions: The first clinical experience at six months suggests that the MSDS strategy was safe and effective to treat femoro-popliteal lesions of considerable length (14.5 ± 9.0 cm). Almost half of the lesion length could be saved from stenting while patency was high and TLR rates were acceptably low.


1993 ◽  
Vol 48 (3) ◽  
pp. 270-276 ◽  
Author(s):  
Jeff Bingaman ◽  
Robert G. Frank ◽  
Carrie L. Billy

Sign in / Sign up

Export Citation Format

Share Document